ReviewFrontiers in endocrinology2026
Estrogen receptors and the NRF2 pathway: bridging hormonal regulation and stress response in the gut.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estradiol, the most potent endogenous estrogen, exerts its biological effects primarily through estrogen receptors, which are expressed in nearly all tissues, including the intestine. Beyond its established roles in reproductive physiology and metabolism, estradiol also influences intestinal motility, barrier integrity, and nutrient absorption. Emerging evidence further indicates that estrogen signaling intersects with NRF2, a central regulator of cellular stress responses and detoxification. This interplay suggests that estrogen may contribute to gut homeostasis by limiting cellular damage and enhancing adaptive defense mechanisms. Accordingly, a clearer understanding of estrogen receptor-NRF2 crosstalk in the intestine may inform new therapeutic strategies for gastrointestinal and metabolic disorders. In this review, we synthesize current evidence on estrogen signaling and NRF2 function in the gastrointestinal tract, with particular emphasis on their emerging interactions and potential roles in intestinal homeostasis. We also integrate findings from extra-intestinal models to outline regulatory networks that may shape estrogen-NRF2 crosstalk in the gut and discuss the potential contributions of the microgenderome and the possible clinical relevance of estrogen receptor-associated NRF2 modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.